Bloomage BioTechnology Corporation Limited
688363.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.69B
Close$
$4.40
87.3% downside
Current Fair Value
87.3% downsideOvervalued by 87.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.69 Billion |
|---|---|
| Enterprise Value | $16.31 Billion |
| Dividend Yield | $0.19 (0.54%) |
| Earnings per Share | $0.61 |
| Beta | 0.51 |
| Outstanding Shares | 493,116,964 |
Return
| Return on Equity | 3.16% |
|---|---|
| Return on Assets | 2.52% |
| Return on Invested Capital | 2.97% |
Valuation & Multiples
| P/E Ratio | 74.4 |
|---|---|
| PEG | -287.14 |
| Price to Sales | 4.95 |
| Price to Book Ratio | 2.47 |
| Enterprise Value to Revenue | 4.43 |
| Enterprise Value to EBIT | 72.81 |
| Enterprise Value to Net Income | 72 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$1.02 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$773.90 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bloomage BioTechnology Corporation Limited
3,698 employees
CEO: Yan Zhao Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophtha...